Cocrystal Pharma (COCP) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Cocrystal Pharma (COCP) over the past year, gaining 63.9% versus a gain of 5.6%. Over five years, COCP leads with a -91.8% price change compared with -99.4% for KTTA. Cocrystal Pharma is the larger company by market cap ($18.3 million vs $17.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | KTTA |
|---|---|---|
| Share price | $0.95 | $0.4787 |
| Market cap | $18.30M | $17.59M |
| 1-day change | -2.05% | -0.48% |
| YTD return | -3.06% | -62.89% |
| 1-year return | +5.56% | +63.94% |
| 5-year return | -91.84% | -99.40% |
| EPS (TTM) | $-0.76 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-8.83M | $-20.43M |
| 52-week high | $2.03 | $2.06 |
| 52-week low | $0.76 | $0.32 |
| Distance from 52-week high | -53.20% | -76.76% |
| Analyst consensus | none | none |
| Avg. price target upside | +847.37% | +526.70% |
| Average volume | 40.65K | 705.64K |
| Shares outstanding | 19.26M | 36.75M |
| Employees | 10 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed COCP by 58.4 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
COCP vs KTTA FAQ
Which is bigger, Cocrystal Pharma or Pasithea Therapeutics?
Cocrystal Pharma (COCP) is larger, with a market capitalization of $18.30M compared with $17.59M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, COCP or KTTA?
KTTA returned +63.94% over the past 12 months, compared with +5.56% for COCP (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.